Investment Rating - The report maintains an "Outperform" rating for Shanxi Jinbo Bio-Pharmaceutical, with a target price of RMB 297.04, indicating a potential upside of 16.3% from the current price of RMB 243.02 [2][15][16]. Core Insights - The core business growth has slowed, with revenue for 9M25 reaching RMB 1.296 billion, a year-on-year increase of 31.10%, while Q3 revenue was RMB 437 million, reflecting a slowdown to 13.36% year-on-year growth [3][12]. - The gross margin has declined, with a 9M25 gross margin of 90.8%, down 1.6 percentage points year-on-year, and a Q3 gross margin of 91.0%, down 2.6 percentage points year-on-year [3][12]. - Rising expenses are impacting profitability, with the sales expense ratio increasing to 22.3% in 9M25, up 5.0 percentage points year-on-year, and R&D expense ratio rising to 5.5%, up 1.1 percentage points year-on-year [3][12]. - The company is expanding production capacity significantly, with fixed assets under construction increasing by 1,074.29% from the beginning of the year, primarily for the production facility of injectable recombinant humanized collagen [4][13]. - The brand "Tongpin" achieved significant sales during the Double 11 shopping festival, generating approximately RMB 76 million in GMV, a 585% year-on-year increase [4][13]. Financial Summary - Revenue forecasts for 2025, 2026, and 2027 are RMB 1.863 billion, RMB 2.402 billion, and RMB 3.073 billion, with year-on-year growth rates of 29.1%, 28.9%, and 27.9% respectively [7][15]. - Net profit forecasts for the same period are RMB 820 million, RMB 1.067 billion, and RMB 1.362 billion, with growth rates of 12%, 30%, and 28% respectively [7][15]. - The report highlights a challenge in balancing cost control and growth quality, as sales expenses are growing faster than revenue [7][15].